Results 191 to 200 of about 691,603 (403)
Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD [PDF]
Wonseok Kang, Seung Up Kim
doaj +1 more source
QuickStroop for screening for minimal hepatic encephalopathy in patients with cirrhosis
Background & Aims: QuickStroop, a shortened version of the Stroop EncephalApp, has recently been proposed for screening for minimal hepatic encephalopathy (MHE) in patients with cirrhosis in the USA.
Christian Labenz +13 more
doaj +1 more source
The experimental production of hepatic cirrhosis [PDF]
Vaughan Harley, Wakelin Barratt
openalex +1 more source
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi +11 more
wiley +1 more source
Health disparities in chronic liver disease
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian +3 more
wiley +1 more source
THE EFFECTS OF PITRESSIN ON THE METABOLISM AND EXCRETION OF WATER AND ELECTROLYTES IN NORMAL SUBJECTS AND PATIENTS WITH CIRRHOSIS AND ASCITES 12 [PDF]
William P. Nelson, L. G. Welt
openalex +1 more source
Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou +6 more
wiley +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
A Clarification of Some Hemodynamic Changes in Cirrhosis and Their Surgical Significance
W. Dean Warren, William H. Muller
openalex +2 more sources

